|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By Anita Dushyanth, PhD NASDAQ:BOTA Following the successful Single Ascending Dose (SAD) study, Biota (NASDAQ:BOTA) completed the Phase 1 multiple ascending dose (MAD) study in the beginning of 2016. The ...
Click here to see latest analysisBiota Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2015.We analyze the earnings along side the following peers of Biota Pharmaceuticals, Inc. – GlaxoSmithKline plc Sponsored ADR (GSK-US) that have also reported for this period.HighlightsNarrowing of operating margins contributed to decline in earnings.The table below shows the […] (Read more...) The post Biota Pharmaceuticals, Inc. Earnings Analysis: Q2, 2016 By the Numbers appeared first on CapitalCube.
Lower respiratory tract infections are induced by various viruses. During the beginning of fall and spring seasons, these viruses contribute significantly to the incidence of viral respiratory tract infections.